The US Food and Drug Administration last week granted accelerated approval
for pembrolizumab (Keytruda), an
immunotherapy drug known as a checkpoint inhibitor, for people with
hepatocellular carcinoma (HCC).
Over
years or decades chronic hepatitis B ...